s6y

Caris Life Sciences, Inc.

Nasdaq
CAI
CIK
2019410
Industry
Services-Medical Laboratories
Based in
Irving, Texas
Incorporated in
Texas
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer, Emerging growth company
Employer ID (EIN)
85-2077369

About

AI summary. This paragraph was summarized by AI from the company’s annual report. It may contain mistakes: check it against the source. How it was written

Caris Life Sciences, Inc. describes itself as an AI TechBio and precision medicine company that develops and commercializes molecular profiling solutions combining comprehensive molecular information with artificial intelligence and machine learning, with an initial focus on oncology. Its Molecular Intelligence portfolio includes the MI Profile Platform for tissue-based whole exome and whole transcriptome sequencing, including the FDA-approved MI Cancer Seek assay; the Caris Assure Platform for blood-based profiling; and the Precision Whole Genome Platform. Its platform is organized around Molecular Intelligence, Caris Discovery, Caris Strategic Data and Caris Infrastructure. Customers include treating physicians, academic researchers and biopharma partners. Caris offers its tests across the United States and Puerto Rico, and internationally through distributors and hospital contracts.

Source: the Business section of the company’s 10-K filed Mar 3, 2026.

Key figures

Fiscal year to Dec 2025
Revenue $812.0M
Operating income $45.1M
Net income −$68.1M
Diluted EPS −$3.22
Cash from operations $83.2M
Total assets $1.13B
Shareholders’ equity $577.3M

From the company’s annual reports to the SEC. Each year links to its report.

Financials 6

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025

News 12

  1. 8-K Financial results
  2. 8-K Regulation FD disclosure
  3. 8-K Financial results
  4. 8-K Shareholder vote results
  5. 8-K Financial results
  6. 8-K Material agreement; Material agreement ended; New debt or obligation
  7. 8-K Financial results; Regulation FD disclosure
  8. 8-K Financial results; Regulation FD disclosure
  9. 8-K Financial results
  10. 8-K Change to shareholder rights; Charter or bylaw change

All 12 news filings

Ownership 87

  1. SCHEDULE 13G/A FMR LLC: Major shareholder report (passive investor)
  2. 4 Denton John Russel: Change in insider ownership
  3. 144 Denton John Russel: Notice of proposed sale of restricted stock
  4. 4 Brille Brian J: Change in insider ownership
  5. 144 Brille Brian J: Notice of proposed sale of restricted stock
  6. 4 Spetzler David Baxley: Change in insider ownership
  7. 144 Spetzler David Baxley: Notice of proposed sale of restricted stock
  8. 144 Spetzler David Baxley: Notice of proposed sale of restricted stock
  9. 144 Poste George: Notice of proposed sale of restricted stock
  10. 4 Fredrickson David Paul: Change in insider ownership

All 87 ownership filings

Prospectus 15

  1. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. S-1/A General form of registration statement for all companies including face-amount certificate companies
  4. S-1/A General form of registration statement for all companies including face-amount certificate companies
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  7. DRSLTR Correspondence Related to Draft Registration Statement
  8. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. DRSLTR Correspondence Related to Draft Registration Statement
  10. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

All 15 prospectus filings

Proxies 2

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements

Other 12

  1. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  2. CERT Certification by an exchange approving securities for listing
  3. ARS Annual report to security holders
  4. EFFECT Notice of Effectiveness
  5. CERT Certification by an exchange approving securities for listing
  6. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. UPLOAD Letter (PDF)

All 12 other filings

Others in Services-Medical Laboratories

Every company in this industry